Influence Of CYP2C19Gene Polymorphisms On The Drug Efficacy Of Paclitaxel And Cisplatin With Advanced Non-small Cell Lung Cancer

Background and objectiveLung cancer,as the most common malignant tumor,has been one of the most seriousdiseases threatening human health,the morbidity and mortality increase rapidly.NSCLC is themost common type of lung cancer,it accounts for about75%-85%,when found thedisease,about2/3patients have lost the chance of operation.chemotherapy is still extremelyimportant in the therapy of lung cancer.selecting the chemotherapy of low toxicity and highefficacy has been the main research direction.The CYP2C19is an important drug metabolizing enzymes,it involves a variety of drugmetabolism in human bodies,it is a member of P450,consists in the liver microsomes,canaffect the metabolism of many drugs,in recent years,its clinical application has been paid moreand more attention.The purpose to study the association between CYP2C19gene polymorphisms and thedrug efficacy and adverse drug reactions of paclitaxel and cisplatin in non-small celllung cancer (NSCLC).Materials and Methods78cases of untreated and advanced non-small cell lung cancer patients were collected from the First Affiliated Hospital of Zhengzhou University betweenFebruary2011and March2013,they were all confirmed by pathology section.we usethe gene chip to detect the polymorphisms of CYP2C19in non-small cell in lungcancer patients,Patients were divided into EM group and PM group according toCYP2C19genotype,the two groups were respectively accepted the chemotherapy ofPaclitaxel plus Cisplatin. after2cycles,drug responses and and cytotoxic reactions wereassessed by WHO criteria,the dates were analyzed using SPSS13.0,The dates formthe clinical effect and adverse reaction rates between the two groups were analyzedwith χ2test,P＜0.05,the results were considered statistical significant.ResultIn the87cases patients with non small cell lung cancer,65cases (74.4%)wereEMs,22cases (25.5%) were PMs,The total effective rate of EM group and PM groupswas52.3%and50.0%respectively，the disease control rate was81.3%and77.3%respectively, P>0.05.The incidence rate of nausea、vomit、muscle soreness in EMgroup was lower than that in PM group,P<0.05.ConclusionThe gene polymorphisms of CYP2C19would not affect the curative effect ofpaclitaxel and cisplatin in non-small cell lung cancer,it can effect the adverse drugreactions.